Published Data — Multicenter, Retrospective Cohort In-Hospital Mortality in Patients with COVID-19 Treated with Hydroxychloroquine and/or Azithromycin (New York State) Source: Rosenberg ES, et al. JAMA 2020 May 11;e208630
In-Hospital Mortality in Patients with COVID-19 Treated with Hydroxychloroquine and/or Azithromycin: Study Design Study Design • Background : Random sample of patients with COVID-19 treated with hydroxychloroquine and/or azithromycin • Location : New York City metropolitan region • Inclusion Criteria (n = 1438) - Confirmed SARS-CoV-2 infection by PCR - In-patient care in a facility with ≥45 patients with COVID-19 - Admitted to hospital for at least 24 hours • Primary outcome: - In-hospital mortality - Viral clearance as assessed by PCR and viral culture • Secondary Outcomes - Cardiac arrest - Abnormal EKG (defined as arrhythmia or QT prolongation) Source: Rosenberg ES, et al. JAMA 2020 May 11;e208630.
In-Hospital Mortality in Patients with COVID-19 Treated with Hydroxychloroquine and/or Azithromycin: Study Design Treatment Groups* Hydroxychloroquine and Azithromycin or Hydroxychloroquine alone or Azithromycin alone or Neither drug *Patients were selected by hospital-stratified random sampling Source: Rosenberg ES, et al. JAMA 2020 May 11;e208630.
In-Hospital Mortality in Patients with COVID-19 Treated with Hydroxychloroquine and/or Azithromycin: Baseline Characteristics HCQ + HCQ Azithromycin Neither drug Azithromycin alone alone Patient Characteristic, n (%) (n = 221) (n = 735) (n = 271) (n = 211) Age, years* < 18 1 (0.1) 2 (0.7) 3 (1.4) 19 (8.6) 18 – 30 23 (3.1) 13 (4.8) 9 (4.3) 8 (3.6) 31 – 44 105 (14.3) 29 (10.7) 29 (13.7) 34 (15.4) 45 – 64 284 (38.6) 90 (33.2) 72 (34.1) 58 (26.2) ≥ 65 322 (43.8) 137 (50.6) 98 (46.5) 102 (46.2) Male sex** 456 (62.0) 158 (58.3) 134 (63.5) 110 (49.8) *P-value < 0.001; **P-value 0.006 Source: Rosenberg ES, et al. JAMA 2020 May 11;e208630.
In-Hospital Mortality in Patients with COVID-19 Treated with Hydroxychloroquine and/or Azithromycin: Baseline Characteristics HCQ + HCQ Azithromycin Patient Characteristics, Neither drug Azithromycin alone alone n (%) (n = 221) (n = 735 ) (n = 271) (n = 211) Preexisting conditions Cardiovascular Disease* 214 (29.1) 99 (36.5) 54 (25.6) 71 (32.1) Diabetes** 269 (36.6) 113 (41.7) 58 ( 27.5) 64 (29.0) BMI ≥ 30*** 264/567 (46.6) 78/188 (41.5) 57/145 (39.3) 39/130 (30.0) * P-value 0.04; **P-value 0.002; ***P-value 0.005 Source: Rosenberg ES, et al. JAMA 2020 May 11;e208630.
In-Hospital Mortality in Patients with COVID-19 Treated with Hydroxychloroquine and/or Azithromycin: Baseline Characteristics HCQ + HCQ Azithromycin Patient Characteristic, Neither drug Azithromycin alone alone n (%) (n = 221) (n = 735 ) (n = 271) (n = 211) SpO 2 within 24 hours of administration* < 90% 149/712 (20.9) 33/252 (17.4) 19/204 (9.3) 13/197 (6.6) 90% – 93% 161/712 (22.6) 41/252 (16.3) 28/204 (13.7) 20/197 (10.2) > 93% 400/712 (56.5) 178/252 (70.6) 157/204 (77.0) 164/197 (83.3) COVID-19 diagnosis prior 113/716 (15.8) 36/266 (13.5) 25/193 (13.0) 19/209 (9.1) to administration *P-value < 0.001 Source: Rosenberg ES, et al. JAMA 2020 May 11;e208630.
In-Hospital Mortality in Patients with COVID-19 Treated with Hydroxychloroquine and/or Azithromycin: Results Outcome*, estimate (95% CI) HCQ + HCQ Azithromycin as compared to neither drug Azithromycin alone alone In-hospital death (hazard ratio) 1.35 (0.76 – 2.40) 1.08 (0.63 – 1.85) 0.56 (0.26 – 1.21) Cardiac Arrest (odds ratio) 2.13 (1.12 – 4.05) 1.91 (0.96 – 3.81) 0.64 (0.27 – 1.56) Abnormal EKG Findings 1.55 (0.89-2.67) 1.50 (0.88-2.58) 0.95 (0.47-1.94) (odds ratio) *Models adjusted for sex, age category, diabetes, chronic lung disease, cardiovascular disease, and abnormal chest imaging Source: Rosenberg ES, et al. JAMA 2020 May 11;e208630.
In-Hospital Mortality in Patients with COVID-19 Treated with Hydroxychloroquine and/or Azithromycin: Authors’ Conclusions Conclusions and relevance : “Among patients hospitalized in metropolitan New York with COVID-19, treatment with hydroxychloroquine, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality.” Source: Rosenberg ES, et al. JAMA 2020 May 11;e208630.
Recommend
More recommend
